vimarsana.com

Latest Breaking News On - Prnewswire biotheryx inc - Page 1 : vimarsana.com

Biotheryx to Present New Preclinical Data on Bifunctional Degraders for CDK4/6 and SOS1 at 2023 ASCO Annual Meeting

/PRNewswire/ Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on.

United statesKyle begovichHannah majeskiPhilippe drouetPrnewswire biotheryx incAmerican society of clinical oncologyClinical oncologyAnnual meetingChief executive officerMeeting presentation detailsPrincipal scientistBreast cancerSenior scientistDevelopmental therapeuticsMolecularly targeted agentsTumor biology

Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets

/PRNewswire/ Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on.

Dashyant dhanakPhilippe drouetResearch collaborationPrnewswire biotheryx incChief executive officerExecutive vice presidentChief scientific officer

Biotheryx to Participate in Wells Fargo 2023 Targeted Protein Degradation Virtual Summit

/PRNewswire/ Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs).

Aparajita hoskote chourasiaLeah fungPrnewswire biotheryx incPanel discussionWells fargoProtein degradation virtual summitOvercoming resistanceTargeted proteinVice presidentTargeted protein degradation make senseChief scientific

Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer

/PRNewswire/ Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs).

Philippe drouetTracy lawhonIndiana universityAdastra pharmaceuticals incIndiana university school of lawPlough research instituteClinical operations at valo health incCabrellis pharmaceuticalsPrnewswire biotheryx incStrategic developmentChief development officerChief executive officerVice presidentClinical operationsValo health incAdastra pharmaceuticals

Biotheryx to Present Preclinical Data for Its Dual Protein Degrader BTX-1188 at the 2022 American Society of Clinical Oncology Annual Meeting

/PRNewswire/ Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs).

United statesIkaros aiolosAparajita hoskote chourasiaPhilippe drouetLeah fungAmerican society of clinical oncologyBiotheryx incDrug administrationPrnewswire biotheryx incDevelopment for the treatment of hematologicBeneficial immunomodulatory propertiesDurable dual degradationVitro alongBeneficial immunomodulatorySupport ongoing phaseSolid tumor

vimarsana © 2020. All Rights Reserved.